Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 9453072 Anti-IL-33 antibodies

Patent 9453072 was granted and assigned to Regeneron Pharmaceuticals on September, 2016 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
0
Date Filed
March 12, 2014
0
Date of Patent
September 27, 2016
0
Patent Applicant
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
0
Patent Application Number
14205512
0
Patent Citations Received
‌
US Patent 12092634 Methods for quantifying IL-33
0
‌
US Patent 11708415 Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1
0
‌
US Patent 11760797 Anti-interleukin-33 antibodies and uses thereof
‌
US Patent 11835527 Deglycosylation methods for electrophoresis of glycosylated proteins
0
‌
US Patent 11866503 Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor
0
‌
US Patent 11963521 Humanized IL-4 and IL-4Rα animals
0
‌
US Patent 11999783 Method of treating autoimmune disease with antibodies against IL-33
0
Patent Inventor Names
Nicholas J. Papadopoulos
0
Andrew J. Murphy
0
Jamie M. Orengo
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
9453072
0
Patent Primary Examiner
‌
Prema Mertz
0

Find more entities like US Patent 9453072 Anti-IL-33 antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.